Table 2. First-, second-, and third-line treatments used in ≥2% of patients by treatment line in the CLL-2 cohort.
| First-line treatment N = 930 |
Second-line treatment N = 352 |
Third-line treatment N = 160 |
|||||
|---|---|---|---|---|---|---|---|
| F | 165 (17.7%) | Ibrutinib | 37 (10.5%) | Ibrutinib | 22 (13.8%) | ||
| C | 127 (13.7%) | BR | 35 (9.9%) | F | 12 (7.5%) | ||
| BR | 76 (8.2%) | B | 23 (6.5%) | BR | 9 (5.6%) | ||
| Methotrexate | 60 (6.5%) | R | 23 (6.5%) | B | 8 (5.0%) | ||
| R | 49 (5.3%) | F | 19 (5.4%) | Etoposide | 8 (5.0%) | ||
| R-CHOP | 46 (4.9%) | Ofatumumab | 18 (5.1%) | R | 6 (3.8%) | ||
| FR | 42 (4.5%) | C | 10 (2.8%) | C | 4 (2.5%) | ||
| FCR | 35 (3.8%) | FCR | 10 (2.8%) | Ofatumumab | 4 (2.5%) | ||
| FC | 32 (3.4%) | R-CHOP | 9 (2.6%) | R-EPOCH | 4 (2.5%) | ||
| B | 27 (2.9%) | Etoposide | 8 (2.3%) | R-ICE | 4 (2.5%) | ||
| Ibrutinib | 24 (2.6%) | ||||||
F, fludarabine; C, cyclophosphamide; B, bendamustine; R, rituximab; CHOP, cyclophosphamide/doxorubicin/vincristine/prednisolone; EPOCH, etoposide/prednisolone/vincristine/cyclophosphamide/doxorubicin; ICE, ifosfamide/carboplatin/etoposide